Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase Ib Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Kazia Therapeutics provided a clinical update from its ongoing Phase Ib study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage, Stage IV, metastatic TNBC.